KP
GTBP icon

Keel Point’s GT Biopharma GTBP Stock Holding History

Keel Point’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.47K Buy
+20,768
New +$11.3K ﹤0.01% 465

Other funds holding GTBP

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SWM
SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
I
INVST Indianapolis, Indiana $886M AUM 21.79% 1-Year Est. Return

Keel Point's GTBP Position: Q1 2026 in Review

Keel Point opened a new position in GT Biopharma (GTBP) in Q1 2026: 20,768 shares worth $8.47K. The stake represents ﹤0.01% of the portfolio and ranks #465 among its holdings.

42 funds tracked by Wall St. Rank hold GTBP as of Q1 2026.

  • Keel Point held 20,768 shares of GT Biopharma worth $8.47K as of Q1 2026.
  • GT Biopharma was a new Keel Point position in Q1 2026.
  • GT Biopharma made up ﹤0.01% of Keel Point's portfolio in Q1 2026, its #465 holding.
  • 42 funds tracked by Wall St. Rank held GT Biopharma as of Q1 2026.

Based on Keel Point's 13F filing for Q1 2026, filed 1 Jun 2026.